Core Viewpoint - Novo Nordisk is facing significant challenges and competition, leading to a downgrade in stock recommendation and a decline in share price [1][2]. Company Performance - Analyst John Eade downgraded Novo Nordisk's stock recommendation from buy to hold, with a new price target of $56 per share [2]. - The company's stock price fell by more than 2% during mid-session trading, closing at $46.86 [1][6]. Market Share and Competition - Novo Nordisk has experienced declines in market share for its leading drugs, Wegovy and Ozempic, and is expected to face further challenges with the introduction of generic competitors [4]. - The company is also competing against Eli Lilly, which has launched a popular obesity drug, Zepbound [7]. Clinical Trials and Research - Recent clinical trials for semaglutide, the active ingredient in Wegovy and Ozempic, have not met expectations, particularly in trials aimed at treating Alzheimer's disease [5]. - The molecule did not slow the progression of Alzheimer's as anticipated, raising concerns about the company's research progress [5]. Financial Metrics - Novo Nordisk has a market capitalization of $161 billion, with a gross margin of 81.93% and a dividend yield of 3.61% [7].